Quarterly report [Sections 13 or 15(d)]

Related Parties

v3.26.3
Related Parties
 9 Months Ended
Sep. 30, 2026
Related Parties  
Related Parties

12Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design and planning, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member is the Company’s Chief Medical Officer (“CMO”). From time to time, the Company contracts the services of the CMO’s spouse through Gendreau to perform certain activities in connection with the Company’s ongoing clinical development of its product candidates.  In the past, the Company has contracted the CMO’s spouse to serve as the Company’s Medical Monitor.  Currently, the Company has contracted the services of the CMO’s spouse to serve as the Company’s Chief Safety Officer for the HALT-CINP-203 clinical trial. In addition, the Company has contracted the services of the CMO’s daughter to serve as an assistant for various clinical site related activities. During the three and nine months ended September 30, 2026 and 2025, the Company paid Gendreau $85,105 and $228,262, respectively and $76,915

and $317,492, respectively, and had accrued liabilities of $38,172 to Gendreau as of September 30, 2026 and had accounts payable to Gendreau of $14,335 as of December 31, 2025.

See Note 9 – “Promissory Note with Related Party” for discussion of related party promissory note with Conjoint Inc.